21731-96-4

Usage

Uses

Used in Medicinal Chemistry:
5-amino-N-methyl-1H-1,2,4-triazole-1-carbothioamide is used as a candidate for the development of antifungal or antimicrobial agents due to its unique structural features and potential to interact with biological targets, offering a new avenue for combating resistant strains of fungi and bacteria.
Used in Agricultural Chemicals:
In the agricultural sector, 5-amino-N-methyl-1H-1,2,4-triazole-1-carbothioamide is utilized as a component in the formulation of pesticides or fungicides, leveraging its antimicrobial properties to protect crops from various pathogens and enhance agricultural productivity.
Used as a Research Tool in Biochemistry:
5-amino-N-methyl-1H-1,2,4-triazole-1-carbothioamide serves as a valuable research tool in biochemistry, where it can be employed to study the interactions of biological molecules and to develop new methodologies for understanding complex biochemical processes.
Further research and development are essential to fully explore the potential of 5-amino-N-methyl-1H-1,2,4-triazole-1-carbothioamide and to discover additional applications that could benefit various industries and scientific fields.

Upstream product

• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 556-61-6 methyl thioisocyanate 

Downstream Products

• 35101-92-9 NSC145180 

Relevant academic research and scientific papers

Antimicrobial and anti-biofilm activity of thiourea derivatives bearing 3-amino-1H-1,2,4-triazole scaffold

A set of 21 thiourea derivatives were prepared through reacting 3-amino-1H-1,2,4-triazole with the commercial aliphatic and aromatic isothiocyanates. The aliphatic isothiocyanate was used as a reagent leading to substitution on NH atom of 3-aminotriazole

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.